StemCells says that a "major international pharmaceutical company" has licensed the company's Ribosome Entry Site (IRES) technology. IRES technology helps researchers evaluate the success of gene knock-outs or knock-ins in stem cells, as well as the successful creation of transgenic mouse and rat disease models. Financial details were not disclosed. This is the third non-exclusive licensing deal StemCells has signed in the last three months. StemCells release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/stemcells-inc-announces-license-agreement-major-pharmaceutical-company-covering-gene-